Clinical Trial: Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891156) titled 'Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.' on Aug. 09.

Brief Summary: The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity.

The main question to answer is:

What effect does Semaglutide have on body composition in adults with type 1 diabetes and overweight/obesity compared to a placebo?

Around 40 participants will:

* Be randomly assigned to receive semaglutide or a placebo.

* Self-administer the treatment drug once per week for 24 weeks.

* C...